Table 2.

Selected shared immune checkpoint receptors between NK cells and T cells.

Receptor	Cell distribution	Drugs approved or in advanced clinical trials	Phase
PD-1	NK cells, T cells, B cells, myeloid cells	Pembrolizumab	FDA Approved
		Nivolumab	FDA Approved
		Cemiplimab	FDA Approved
		Dostarlimab	FDA Approved
		Tislelizumab	Phase III in US; approved in China
TIGIT	NK cells, T cells	Tiragolumab	Phase III
		Vibostolimab	Phase III
		Ociperlimab	Phase III
TIM3	NK cells, T cells, DCs, monocytes, macrophages, mast cells	MBG453	Phase II
		BGB-A425	Phase I/II
		TSR-022	Phase II
NKG2A	NK cells and T cells	Monalizumab	Phase III